Immunocore Holdings Plc-adr (IMCR)

$33.24

-1.14

(-3.32%)▲

Live

Performance

  • $33.01
    $34.62
    $33.24
    downward going graph

    0.69%

    Downside

    Day's Volatility :4.65%

    Upside

    3.99%

    downward going graph
  • $29.72
    $76.98
    $33.24
    downward going graph

    10.59%

    Downside

    52 Weeks Volatility :61.39%

    Upside

    56.82%

    downward going graph

Returns

PeriodImmunocore Holdings Plc-adrSector (Health Care)Index (Russel 2000)
3 Months
-12.47%
3.6%
0.0%
6 Months
-38.41%
10.2%
0.0%
1 Year
-25.68%
19.6%
0.0%
3 Years
-8.9%
16.8%
-23.0%

Highlights

Market Capitalization
1.7B
Book Value
$7.18
Earnings Per Share (EPS)
-1.1
Wall Street Target Price
80.79
Profit Margin
-19.53%
Operating Margin TTM
-21.24%
Return On Assets TTM
-5.89%
Return On Equity TTM
-15.43%
Revenue TTM
280.9M
Revenue Per Share TTM
5.66
Quarterly Revenue Growth YOY
26.200000000000003%
Gross Profit TTM
54.1M
EBITDA
-70.5M
Diluted Eps TTM
-1.1
Quarterly Earnings Growth YOY
-0.68
EPS Estimate Current Year
-1.51
EPS Estimate Next Year
-2.06
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 24 Wall street analysts offering stock ratings for Immunocore Holdings Plc-adr(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
21
21
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 143.05%

Current $33.24
Target $80.79

Company Financials

FY18Y/Y Change
Revenue
30.0M
-
Net Income
-90.7M
-
Net Profit Margin
-302.82%
-
FY19Y/Y Change
Revenue
33.6M
↑ 8.52%
Net Income
-136.1M
↑ 45.09%
Net Profit Margin
-404.89%
↓ 102.07%
FY20Y/Y Change
Revenue
40.5M
↑ 17.32%
Net Income
-99.5M
↓ 28.71%
Net Profit Margin
-246.04%
↑ 158.85%
FY21Y/Y Change
Revenue
35.3M
↓ 11.93%
Net Income
-175.0M
↑ 77.51%
Net Profit Margin
-495.94%
↓ 249.9%
FY22Y/Y Change
Revenue
175.0M
↑ 441.99%
Net Income
-50.2M
↓ 68.66%
Net Profit Margin
-28.68%
↑ 467.26%
FY23Y/Y Change
Revenue
315.8M
↑ 73.53%
Net Income
-70.0M
↑ 34.11%
Net Profit Margin
-22.17%
↑ 6.51%
Q1 FY23Q/Q Change
Revenue
54.0M
↓ 7.33%
Net Income
-20.3M
↓ 33.75%
Net Profit Margin
-37.49%
↑ 14.95%
Q2 FY23Q/Q Change
Revenue
60.3M
↑ 7.24%
Net Income
-17.8M
↓ 15.69%
Net Profit Margin
-29.47%
↑ 8.02%
Q3 FY23Q/Q Change
Revenue
77.7M
↑ 31.11%
Net Income
2.9M
↓ 116.45%
Net Profit Margin
3.7%
↑ 33.17%
Q4 FY23Q/Q Change
Revenue
133.7M
↑ 68.68%
Net Income
-33.4M
↓ 1240.71%
Net Profit Margin
-25.01%
↓ 28.71%
Q1 FY24Q/Q Change
Revenue
89.6M
↓ 33.26%
Net Income
-31.1M
↓ 7.5%
Net Profit Margin
-34.66%
↓ 9.65%
Q2 FY24Q/Q Change
Revenue
75.4M
↑ 6.95%
Net Income
-11.6M
↓ 52.46%
Net Profit Margin
-15.41%
↑ 19.25%
FY18Y/Y Change
Total Assets
247.9M
-
Total Liabilities
176.3M
-
FY19Y/Y Change
Total Assets
243.1M
↓ 5.17%
Total Liabilities
223.7M
↑ 22.76%
FY20Y/Y Change
Total Assets
264.9M
↑ 6.22%
Total Liabilities
190.5M
↓ 16.99%
FY21Y/Y Change
Total Assets
401.5M
↑ 53.03%
Total Liabilities
173.3M
↓ 8.19%
FY22Y/Y Change
Total Assets
530.2M
↑ 44.32%
Total Liabilities
190.8M
↑ 20.38%
FY23Y/Y Change
Total Assets
597.0M
↑ 37.08%
Total Liabilities
228.2M
↑ 45.54%
Q1 FY23Q/Q Change
Total Assets
522.3M
↓ 1.14%
Total Liabilities
189.8M
↓ 0.2%
Q2 FY23Q/Q Change
Total Assets
556.1M
↑ 2.28%
Total Liabilities
205.9M
↑ 4.25%
Q3 FY23Q/Q Change
Total Assets
700.6M
↑ 28.19%
Total Liabilities
260.5M
↑ 28.71%
Q4 FY23Q/Q Change
Total Assets
755.8M
↑ 5.76%
Total Liabilities
288.8M
↑ 8.7%
Q1 FY24Q/Q Change
Total Assets
1.3B
↑ 66.5%
Total Liabilities
806.4M
↑ 178.08%
Q2 FY24Q/Q Change
Total Assets
1.0B
↑ 2.96%
Total Liabilities
664.2M
↑ 4.69%
FY18Y/Y Change
Operating Cash Flow
-21.1M
↓ 72.71%
Investing Cash Flow
73.5M
↓ 703.68%
Financing Cash Flow
127.9K
↓ 99.47%
FY19Y/Y Change
Operating Cash Flow
-132.7M
↑ 509.74%
Investing Cash Flow
-5.4M
↓ 107.13%
Financing Cash Flow
72.2M
↑ 54481.19%
FY20Y/Y Change
Operating Cash Flow
-81.4M
↓ 40.25%
Investing Cash Flow
627.3K
↓ 111.29%
Financing Cash Flow
155.7M
↑ 110.32%
FY21Y/Y Change
Operating Cash Flow
-172.6M
↑ 114.2%
Investing Cash Flow
-488.3K
↓ 178.59%
Financing Cash Flow
367.5M
↑ 138.27%
FY22Y/Y Change
Operating Cash Flow
-38.1M
↓ 75.9%
Investing Cash Flow
234.9K
↓ 152.59%
Financing Cash Flow
168.3M
↓ 49.96%
Q1 FY23Q/Q Change
Operating Cash Flow
10.7M
↑ 45.76%
Investing Cash Flow
3.3M
↑ 715.06%
Financing Cash Flow
3.0M
↓ 308.65%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.0M
↓ 127.2%
Investing Cash Flow
3.4M
↑ 0.0%
Financing Cash Flow
9.3M
↑ 196.1%
Q3 FY23Q/Q Change
Operating Cash Flow
7.7M
↓ 360.35%
Investing Cash Flow
2.7M
↓ 20.88%
Financing Cash Flow
9.7M
↑ 6.11%

Technicals Summary

Sell

Neutral

Buy

Immunocore Holdings Plc-adr is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
11.62%
-38.41%
-25.68%
-8.9%
-13.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
NA
NA
NA
-1.51
-0.15
-0.06
NA
7.18
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
Buy
$1.7B
-13.25%
NA
-19.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Immunocore Holdings Plc-adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 70.50M → 75.4M (in $), with an average increase of 6.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -26.41M → -11.61M (in $), with an average increase of 59.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 110.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 53.7%

Institutional Holdings

  • Wellington Management Company LLP

    12.76%

  • RTW INVESTMENTS, LLC

    9.74%

  • FMR Inc

    9.62%

  • T. Rowe Price Investment Management,Inc.

    5.98%

  • T. Rowe Price Associates, Inc.

    5.66%

  • PRIMECAP Management Company

    3.90%

Company Information

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.

Organization
Immunocore Holdings Plc-adr
Employees
497
CEO
Dr. Bahija Jallal Ph.D.
Industry
Services

Discover More

FAQs